{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T11:08:39Z","timestamp":1794136119743,"version":"4.8.0"},"reference-count":93,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T00:00:00Z","timestamp":1696464000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:p>Myasthenia gravis is a prototypic neuroimmune disorder with autoantibodies targeting the acetylcholine receptor complex at the neuromuscular junction. Patients present with mainly ocular muscle weakness and tend to have a generalized muscle weakness later in the clinical course. The weakness can be severe and fatal when bulbar muscles are heavily involved. Acetylcholine receptor antibodies are present in the majority of patients and are of IgG1 and IgG3 subtypes which can activate the complement system. The complement involvement plays a major role in the neuromuscular junction damage and the supporting evidence in the literature is described in this article. Complement therapies were initially studied and approved for paroxysmal nocturnal hemoglobinuria and in the past decade, those have also been studied in myasthenia gravis. The currently available randomized control trial and real-world data on the efficacy and safety of the approved and investigational complement therapies are summarized in this review.<\/jats:p>","DOI":"10.3389\/fneur.2023.1277596","type":"journal-article","created":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T08:38:36Z","timestamp":1696495116000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":25,"title":["Role of complement in myasthenia gravis"],"prefix":"10.3389","volume":"14","author":[{"given":"Pyae Phyo","family":"San","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saiju","family":"Jacob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,10,5]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1136\/jnnp.65.4.492","article-title":"Myasthenia gravis: a population based epidemiological study in Cambridgeshire, England","volume":"65","author":"Robertson","year":"1998","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/1471-2377-10-46","article-title":"A systematic review of population based epidemiological studies in myasthenia gravis","volume":"10","author":"Carr","year":"2010","journal-title":"BMC Neurol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1002\/mus.20950","article-title":"Lifetime course of myasthenia gravis","volume":"37","author":"Grob","year":"2008","journal-title":"Muscle Nerve"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/85520","article-title":"Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies","volume":"7","author":"Hoch","year":"2001","journal-title":"Nat Med"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1002\/ana.22312","article-title":"Autoantibodies to low-density lipoprotein receptor-related protein 4 in myasthenia gravis","volume":"69","author":"Higuchi","year":"2011","journal-title":"Ann Neurol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/s00415-011-6194-7","article-title":"Anti-LRP4 autoantibodies in AChR- and MuSK-antibody-negative myasthenia gravis","volume":"259","author":"Pevzner","year":"2012","journal-title":"J Neurol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1001\/archneurol.2011.2393","article-title":"Autoantibodies to lipoprotein-related protein 4 in patients with double-seronegative myasthenia gravis","volume":"69","author":"Tzartos","year":"2012","journal-title":"Arch Neurol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1111\/j.1600-065X.1998.tb01190.x","article-title":"Anatomy of the antigenic structure of a large memberane autoantigen, the muscle-type nicotinic acetylcholine receptor","volume":"163","author":"Tzartos","year":"1998","journal-title":"Immunol Rev"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/S0968-0004(76)80137-5","article-title":"Experimental myasthenia gravis\u2014a new autoimmune model","volume":"1","author":"Vincent","year":"1976","journal-title":"Trends Biochem Sci"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/S0065-2776(08)60847-0","article-title":"Myasthenia gravis","volume":"42","author":"Lindstrom","year":"1988","journal-title":"Adv Immunol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1073\/pnas.77.2.755","article-title":"Monoclonal antibodies used to probe acetylcholine receptor structure: localization of the main immunogenic region and detection of similarities between subunits","volume":"77","author":"Tzartos","year":"1980","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s12031-009-9271-y","article-title":"Antigenic structure of the human muscle nicotinic acetylcholine receptor main immunogenic region","volume":"40","author":"Luo","year":"2010","journal-title":"J Mol Neurosci"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1136\/jnnp-2019-322640","article-title":"Myasthenia gravis AChR antibodies inhibit function of rapsyn-clustered AChRs","volume":"91","author":"Cetin","year":"2020","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1523\/JNEUROSCI.03-03-00644.1983","article-title":"Fine structural distribution of acetylcholine receptors at developing mouse neuromuscular junctions","volume":"3","author":"Matthews-Bellinger","year":"1983","journal-title":"J Neurosci"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1111\/j.1749-6632.1981.tb33730.x","article-title":"The immunopathology of acquired myasthenia gravis","volume":"377","author":"Engel","year":"1981","journal-title":"Ann N Y Acad Sci"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"358","DOI":"10.3390\/cells10020358","article-title":"The metabolic stability of the nicotinic acetylcholine receptor at the neuromuscular junction","volume":"10","author":"Martinez-Pena","year":"2021","journal-title":"Cells"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"3090","DOI":"10.1073\/pnas.74.7.3090","article-title":"Modulation of acetylcholine receptor by antibody against the receptor","volume":"74","author":"Heinemann","year":"1977","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1056\/NEJM198209233071301","article-title":"Functional activities of autoantibodies to acetylcholine receptors and the clinical severity of myasthenia gravis","volume":"307","author":"Drachman","year":"1982","journal-title":"N Engl J Med"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1056\/NEJM197805182982004","article-title":"Myasthenic antibodies cross-link acetylcholine receptors to accelerate degradation","volume":"298","author":"Drachman","year":"1978","journal-title":"N Engl J Med"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/0896-8411(89)90004-8","article-title":"Fab fragments of monoclonal antibodies protect the human acetylcholine receptor against antigenic modulation caused by myasthenic sera","volume":"2","author":"Sophianos","year":"1989","journal-title":"J Autoimmun"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1111\/j.1749-6632.1971.tb30744.x","article-title":"Ultrastructural alterations in muscle from patients with myasthenia gravis and Eaton\u2013Lumbert syndrome","volume":"183","author":"Bergman","year":"1971","journal-title":"Ann N Y Acad Sci"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"4584","DOI":"10.1073\/pnas.73.12.4584","article-title":"Studies of human myasthenia gravis: electrophysiological and ultrastructural evidence compatible with antibody attachment to acetylcholine receptor complex","volume":"73","author":"Rash","year":"1976","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/nri1994","article-title":"T-cell regulation: with complements from innate immunity","volume":"7","author":"Kemper","year":"2007","journal-title":"Nat Rev Immunol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1078\/0171-2985-00141","article-title":"C1q, autoimmunity and apoptosis","volume":"205","author":"Botto","year":"2002","journal-title":"Immunobiology"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/cr.2009.139","article-title":"Complement and its role in innate and adaptive immune responses","volume":"20","author":"Dunkelberger","year":"2010","journal-title":"Cell Res"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"177","DOI":"10.3181\/00379727-105-26050","article-title":"Changes in serum complement activity in patients with myasthenia gravis","volume":"105","author":"Nastuk","year":"1960","journal-title":"Exp Biol Med"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1111\/j.1749-6632.1987.tb51301.x","article-title":"The membrane attack complex of complement at the endplate in myasthenia gravis","volume":"505","author":"Engel","year":"1987","journal-title":"Ann N Y Acad Sci"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1212\/WNL.39.10.1359","article-title":"Diagnostic significance of IgG, C3, and C9 at the limb muscle motor end-plate in minimal myasthenia gravis","volume":"39","author":"Tsujihata","year":"1989","journal-title":"Neurology"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1097\/00005072-197803000-00008","article-title":"Ultrastructural localization of immune complexes (IgG and C3) at the end-plate in experimental autoimmune myasthenia gravis","volume":"37","author":"Sahashi","year":"1978","journal-title":"J Neuropathol Exp Neurol"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.jneuroim.2004.08.002","article-title":"The role of complement in myasthenia gravis: serological evidence of complement consumption in vivo","volume":"158","author":"Romi","year":"2005","journal-title":"J Neuroimmunol"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1002\/mus.21398","article-title":"Correlation of C3 level with severity of generalized myasthenia gravis","volume":"40","author":"Liu","year":"2009","journal-title":"Muscle Nerve"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1001\/archneurol.2012.437","article-title":"Presence and pathogenic relevance of antibodies to clustered acetylcholine receptor in ocular and generalized myasthenia gravis","volume":"69","author":"Jacob","year":"2012","journal-title":"Arch Neurol"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1084\/jem.147.4.973","article-title":"Role of complement in the pathogenesis of experimental autoimmune myasthenia gravis","volume":"147","author":"Lennon","year":"1978","journal-title":"J Exp Med"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"3847","DOI":"10.4049\/jimmunol.171.7.3847","article-title":"Genetic evidence for involvement of classical complement pathway in induction of experimental autoimmune myasthenia gravis","volume":"171","author":"T\u00fcz\u00fcn","year":"2003","journal-title":"J Immunol"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"2589","DOI":"10.4049\/jimmunol.140.8.2589","article-title":"C5 gene influences the development of murine myasthenia gravis","volume":"140","author":"Christadoss","year":"1988","journal-title":"J Immunol"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1111\/j.1365-2249.2006.03198.x","article-title":"Complement membrane attack is required for endplate damage and clinical disease in passive experimental myasthenia gravis in Lewis rats","volume":"146","author":"Chamberlain-Banoub","year":"2006","journal-title":"Clin Exp Immunol"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/0161-5890(79)90010-5","article-title":"Reaction between the isolated globular sub-units of the complement component C1q and IgG-complexes","volume":"16","author":"Hughes-Jones","year":"1979","journal-title":"Mol Immunol"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/0968-0004(90)90178-E","article-title":"Antibody: the flexible adaptor molecule","volume":"15","author":"Burton","year":"1990","journal-title":"Trends Biochem Sci"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1126\/science.1248943","article-title":"Complement is activated by IgG hexamers assembled at the cell surface","volume":"343","author":"Diebolder","year":"2014","journal-title":"Science"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.molcel.2016.05.016","article-title":"Molecular basis of assembly and activation of complement component C1 in complex with immunoglobulin G1 and antigen","volume":"63","author":"Wang","year":"2016","journal-title":"Mol Cell"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"4787","DOI":"10.1021\/acs.nanolett.9b02220","article-title":"Unraveling the macromolecular pathways of IgG oligomerization and complement activation on antigenic surfaces","volume":"19","author":"Strasser","year":"2019","journal-title":"Nano Lett"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/S1567-5769(00)00043-6","article-title":"Membrane complement regulatory proteins: insight from animal studies and relevance to human diseases","volume":"1","author":"Miwa","year":"2001","journal-title":"Int Immunopharmacol"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1146\/annurev.iy.07.040189.000343","article-title":"Decay-accelerating factor: biochemistry, molecular biology, and function","volume":"7","author":"Lublin","year":"1989","journal-title":"Annu Rev Immunol"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1146\/annurev.iy.09.040191.002243","article-title":"Membrane cofactor protein (MCP or CD46): newest member of the regulators of complement activation gene cluster","volume":"9","author":"Liszewski","year":"1991","journal-title":"Annu Rev Immunol"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/S0065-2776(08)60654-9","article-title":"Structure and function of the complement receptors, CR1 (CD35) and CR2 (CD21)","volume":"46","author":"Ahearn","year":"1989","journal-title":"Adv Immunol"},{"key":"ref46","first-page":"1","article-title":"Human protectin (CD59), an 18,000\u201320,000 MW complement lysis restricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers","volume":"71","author":"Meri","year":"1990","journal-title":"Immunology"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"3478","DOI":"10.4049\/jimmunol.144.9.3478","article-title":"The complement-inhibitory activity of CD59 resides in its capacity to block incorporation of C9 into membrane C5b-9","volume":"144","author":"Rollins","year":"1990","journal-title":"J Immunol"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.expneurol.2006.06.003","article-title":"Deficiency of decay accelerating factor and CD59 leads to crisis in experimental myasthenia","volume":"202","author":"Kaminski","year":"2006","journal-title":"Exp Neurol"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1172\/JCI0216086","article-title":"Markedly enhanced susceptibility to experimental autoimmune myasthenia gravis in the absence of decay-accelerating factor protection","volume":"110","author":"Lin","year":"2002","journal-title":"J Clin Invest"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.expneurol.2004.06.005","article-title":"Complement regulators in extraocular muscle and experimental autoimmune myasthenia gravis","volume":"189","author":"Kaminski","year":"2004","journal-title":"Exp Neurol"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1172\/JCI114387","article-title":"Mechanism of therapeutic effect of high-dose intravenous immunoglobulin. Attenuation of acute, complement-dependent immune damage in a guinea pig model","volume":"84","author":"Basta","year":"1989","journal-title":"J Clin Invest"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1038\/nrneurol.2014.253","article-title":"Intravenous immunoglobulin in neurology\u2014mode of action and clinical efficacy","volume":"11","author":"L\u00fcnemann","year":"2015","journal-title":"Nat Rev Neurol"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1056\/NEJMoa1900866","article-title":"Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder","volume":"381","author":"Pittock","year":"2019","journal-title":"N Engl J Med"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1002\/mus.23839","article-title":"A randomized, double-blind, placebo-controlled phase II study of eculizumab in patients with refractory generalized myasthenia gravis","volume":"48","author":"Howard","year":"2013","journal-title":"Muscle Nerve"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","article-title":"Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study","volume":"16","author":"Howard","year":"2017","journal-title":"Lancet Neurol"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1002\/mus.26447","article-title":"Long-term safety and efficacy of eculizumab in generalized myasthenia gravis","volume":"60","author":"Muppidi","year":"2019","journal-title":"Muscle Nerve"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1002\/acn3.51376","article-title":"Long-term efficacy of eculizumab in refractory generalized myasthenia gravis: responder analyses","volume":"8","author":"Howard","year":"2021","journal-title":"Ann Clin Transl Neurol"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1007\/s00415-020-09770-y","article-title":"\u201cMinimal symptom expression\u201d in patients with acetylcholine receptor antibody-positive refractory generalized myasthenia gravis treated with eculizumab","volume":"267","author":"Vissing","year":"2020","journal-title":"J Neurol"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"e610","DOI":"10.1212\/WNL.0000000000011207","article-title":"Post-intervention status in patients with refractory myasthenia gravis treated with eculizumab during REGAIN and its open-label extension","volume":"96","author":"Mantegazza","year":"2021","journal-title":"Neurology"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"175628642091178","DOI":"10.1177\/1756286420911784","article-title":"Response to eculizumab in patients with myasthenia gravis recently treated with chronic IVIg: a subgroup analysis of REGAIN and its open-label extension study","volume":"13","author":"Jacob","year":"2020","journal-title":"Ther Adv Neurol Disord"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1002\/mus.27422","article-title":"Eculizumab in refractory generalized myasthenia gravis previously treated with rituximab: subgroup analysis of REGAIN and its extension study","volume":"64","author":"Siddiqi","year":"2021","journal-title":"Muscle Nerve"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1002\/mus.27326","article-title":"The use of eculizumab in ventilator-dependent myasthenia gravis patients","volume":"64","author":"Usman","year":"2021","journal-title":"Muscle Nerve"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"3125","DOI":"10.1007\/s00415-021-10428-6","article-title":"Complement inhibition initiated recovery of a severe myasthenic crisis with COVID-19","volume":"268","author":"Hofstadt-van Oy","year":"2021","journal-title":"J Neurol"},{"key":"ref64","doi-asserted-by":"publisher","first-page":"287","DOI":"10.3233\/JND-200584","article-title":"Clinical experience with eculizumab in treatment-refractory acetylcholine receptor antibody-positive generalized myasthenia gravis","volume":"8","author":"Katyal","year":"2021","journal-title":"J Neuromuscul Dis"},{"key":"ref65","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1136\/jnnp-2021-328665","article-title":"Eculizumab versus rituximab in generalised myasthenia gravis","volume":"93","author":"Nelke","year":"2022","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref66","doi-asserted-by":"publisher","first-page":"269","DOI":"10.3233\/JND-190464","article-title":"Retrospective analysis of eculizumab in patients with acetylcholine receptor antibody-negative myasthenia gravis: a case series","volume":"7","author":"Datta","year":"2020","journal-title":"J Neuromuscul Dis"},{"key":"ref67","doi-asserted-by":"publisher","first-page":"175628642093203","DOI":"10.1177\/1756286420932035","article-title":"Eculizumab as a promising treatment in thymoma-associated myasthenia gravis","volume":"13","author":"V\u00e9lez-Santamar\u00eda","year":"2020","journal-title":"Ther Adv Neurol Disord"},{"key":"ref68","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ensci.2019.01.006","article-title":"Eculizumab improved weakness and taste disorder in thymoma-associated generalized myasthenia gravis with anti-striational antibodies: a case report","volume":"14","author":"Amano","year":"2019","journal-title":"eNeurologicalSci"},{"key":"ref69","doi-asserted-by":"publisher","first-page":"e921431","DOI":"10.12659\/AJCR.921431","article-title":"Successful transition from plasma exchange to eculizumab in acetylcholine receptor antibody- and muscle-specific kinase (MuSK) antibody-negative myasthenia gravis: a case report","volume":"21","author":"Greenwood","year":"2020","journal-title":"Am J Case Rep"},{"key":"ref70","doi-asserted-by":"publisher","first-page":"119","DOI":"10.18553\/jmcp.2022.28.1.119","article-title":"The effectiveness and value of eculizumab and efgartigimod for generalized myasthenia gravis","volume":"28","author":"Tice","year":"2022","journal-title":"J Manag Care Spec Pharm"},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2100066","article-title":"Terminal complement inhibitor ravulizumab in generalized myasthenia gravis","volume":"1","author":"Vu","year":"2022","journal-title":"NEJM Evid"},{"key":"ref72","doi-asserted-by":"publisher","first-page":"3862","DOI":"10.1007\/s00415-023-11699-x","article-title":"Long-term efficacy and safety of ravulizumab in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis: results from the phase 3 CHAMPION MG open-label extension","volume":"270","author":"Meisel","year":"2023","journal-title":"J Neurol"},{"key":"ref73","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1080\/13543784.2021.1897567","article-title":"Zilucoplan: an investigational complement C5 inhibitor for the treatment of acetylcholine receptor autoantibody-positive generalized myasthenia gravis","volume":"30","author":"Howard","year":"2021","journal-title":"Expert Opin Investig Drugs"},{"key":"ref74","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/S1474-4422(23)00080-7","article-title":"Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study","volume":"22","author":"Howard","year":"2023","journal-title":"Lancet Neurol"},{"key":"ref75","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1182\/blood-2018-99-112262","article-title":"A randomized, double-blind, placebo-controlled phase 1 study of the pharmacokinetics and pharmacodynamics of REGN3918, a human antibody against complement factor C5, in healthy volunteers","volume":"132","author":"Weyne","year":"2018","journal-title":"Blood"},{"key":"ref76","doi-asserted-by":"publisher","first-page":"e0269749","DOI":"10.1371\/journal.pone.0269749","article-title":"Pharmacokinetics and pharmacodynamics of pozelimab alone or in combination with cemdisiran in non-human primates","volume":"17","author":"Devalaraja-Narashimha","year":"2022","journal-title":"PLoS One"},{"key":"ref77","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.molimm.2019.07.030","article-title":"Compendium of current complement therapeutics","volume":"114","author":"Zelek","year":"2019","journal-title":"Mol Immunol"},{"key":"ref78","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1080\/1744666X.2022.2082946","article-title":"Role of complement, anti-complement therapeutics, and other targeted immunotherapies in myasthenia gravis","volume":"18","author":"Dalakas","year":"2022","journal-title":"Expert Rev Clin Immunol"},{"key":"ref79","volume-title":"Food and Drug Administration. Soliris product insert","year":"2017"},{"key":"ref80","volume-title":"Meningococcal ACIP recommendations","year":"2017"},{"key":"ref81","doi-asserted-by":"publisher","first-page":"734","DOI":"10.15585\/mmwr.mm6627e1","article-title":"High risk for invasive meningococcal disease among patients receiving eculizumab (soliris) despite receipt of meningococcal vaccine","volume":"66","author":"McNamara","year":"2017","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"ref82","doi-asserted-by":"publisher","first-page":"207","DOI":"10.2147\/DHPS.S257009","article-title":"Risk analysis of eculizumab-related meningococcal disease in Japan using the Japanese adverse drug event report database","volume":"12","author":"Matsumura","year":"2020","journal-title":"Drug Healthc Patient Saf"},{"key":"ref83","doi-asserted-by":"publisher","first-page":"3615","DOI":"10.1182\/bloodadvances.2020002497","article-title":"Eculizumab impairs Neisseria meningitidis serogroup B killing in whole blood despite 4CMenB vaccination of PNH patients","volume":"4","author":"Langereis","year":"2020","journal-title":"Blood Adv"},{"key":"ref84","volume-title":"Soliris-EPAR-product information","year":""},{"key":"ref85","doi-asserted-by":"publisher","first-page":"e1169","DOI":"10.1212\/NXI.0000000000001169","article-title":"Heterogeneity of acetylcholine receptor autoantibody\u2013mediated complement activity in patients with myasthenia gravis","volume":"9","author":"Obaid","year":"2022","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"ref86","doi-asserted-by":"publisher","first-page":"109551","DOI":"10.1016\/j.jneumeth.2022.109551","article-title":"A bioassay for neuromuscular junction-restricted complement activation by myasthenia gravis acetylcholine receptor antibodies","volume":"373","author":"Plomp","year":"2022","journal-title":"J Neurosci Methods"},{"key":"ref87","doi-asserted-by":"publisher","first-page":"317","DOI":"10.2147\/ITT.S261414","article-title":"Complement inhibition for the treatment of myasthenia gravis","volume":"9","author":"Mantegazza","year":"2020","journal-title":"Immunotargets Ther"},{"key":"ref88","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1007\/s40262-019-00742-8","article-title":"Pharmacology, pharmacokinetics and pharmacodynamics of eculizumab, and possibilities for an individualized approach to eculizumab","volume":"58","author":"Wijnsma","year":"2019","journal-title":"Clin Pharmacokinet"},{"key":"ref89","doi-asserted-by":"publisher","first-page":"105630","DOI":"10.1016\/j.clineuro.2019.105630","article-title":"Temporal correlation between serum CH50 level and symptom severity of myasthenia gravis during eculizumab therapy","volume":"189","author":"Yanagidaira","year":"2020","journal-title":"Clin Neurol Neurosurg"},{"key":"ref90","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1001\/jamaneurol.2019.5125","article-title":"Clinical effects of the self-administered subcutaneous complement inhibitor zilucoplan in patients with moderate to severe generalized myasthenia gravis","volume":"77","author":"Howard","year":"2020","journal-title":"JAMA Neurol"},{"key":"ref91","doi-asserted-by":"publisher","first-page":"e0264489","DOI":"10.1371\/journal.pone.0264489","article-title":"Myasthenia gravis complement activity is independent of autoantibody titer and disease severity","volume":"17","author":"Fichtner","year":"2022","journal-title":"PLoS One"},{"key":"ref92","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1056\/NEJMoa1311084","article-title":"Genetic variants in C5 and poor response to eculizumab","volume":"370","author":"Nishimura","year":"2014","journal-title":"N Engl J Med"},{"key":"ref93","doi-asserted-by":"publisher","first-page":"337","DOI":"10.4049\/jimmunol.1600280","article-title":"Structural basis for eculizumab-mediated inhibition of the complement terminal pathway","volume":"197","author":"Schatz-Jakobsen","year":"2016","journal-title":"J Immunol"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2023.1277596\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T08:38:44Z","timestamp":1696495124000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2023.1277596\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,5]]},"references-count":93,"alternative-id":["10.3389\/fneur.2023.1277596"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2023.1277596","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,5]]},"article-number":"1277596"}}